Skip to content

JBIO JBIO Pre-Tax Income

Pre-Tax Income at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.25B+71.5%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$36.72M+10.8%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$74.9M-96.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$52.84M-34.5%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$19.62M-49.3%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$43.09M+7.1%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's pre-tax income?
JBIO (JBIO) reported pre-tax income of -$40.35M in Q1 2026.
How has JBIO's pre-tax income changed year-over-year?
JBIO's pre-tax income decreased by 5.7% year-over-year, from -$38.17M to -$40.35M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.